Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin

05.08.2004


Scientists have developed an experimental vaccine against ricin, a potential biological threat agent, which fully protected mice from aerosol challenge with lethal doses of the toxin. The study was performed at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

Ricin is a toxin derived from the castor plant, which is grown throughout the world for commercial purposes. Approximately one million pounds of castor beans are used each year in the process of manufacturing castor oil.

When inhaled as a small-particle aerosol, ricin produces severe respiratory symptoms followed by respiratory failure within 72 hours. When ingested, ricin can cause severe gastrointestinal symptoms followed by vascular collapse and death.



Given its ready availability and its high level of toxicity--particularly when delivered as an aerosol--ricin is a significant potential agent of biological warfare or terrorism. Currently, there is no vaccine or therapy available for human use.

According to lead investigator Mark A. Olson, Ph.D., ricin is composed of two different protein subunits called the A-chain and the B-chain. The ricin B-chain (RTB) binds the toxin to the cell surface, an interface that is essential for the ricin A-chain (RTA) to enter the cell. Once inside the cell, RTA effectively stops new protein synthesis and causes cell death.

Previous attempts to develop a ricin vaccine suggested that isolated RTA could induce protective immunity against the toxin in animals. However, using RTA as a vaccine component was problematic because it was not stable--it failed to maintain its structural integrity when heated or placed in solution, resulting in clumping and separation. The safety and efficacy of a vaccine depend upon the stability of its formulation.

The new vaccine candidate, called RTA 1-33/44-198, is a fragment of the ricin A-chain that has been modified to eliminate the toxic enzymatic property of RTA, increase protein stability, and maintain its ability to elicit a protective immune response.

In the August online issue of Protein Engineering, Design and Selection, Olson and his team--John H. Carra, Virginia Roxas-Duncan, Robert W. Wannemacher, Leonard A. Smith, and Charles B. Millard--describe using a combination of molecular modeling and protein engineering to design the new vaccine. The team started with an extensive computer-aided analysis of the toxin structure, using a three-dimensional model provided by colleagues at the University of Texas, Austin.

"We compared ricin with other proteins of the same family," Olson explained. "We tried to figure out where the protein molecules are diverging within the family--to see what changes were made by nature so we could make the changes we needed to make."

To improve upon its stability--in effect, to make it go against its natural tendencies--Olson and his team had to change the structure of the RTA molecule. Once they had developed the necessary genetic sequences, they handed them off to Smith and others at USAMRIID for protein engineering.

"We went straight from the computer to molecular biology," explained Smith. "We had to clone and purify the proteins, and test them in animals for toxicity and protection."

RTA 1-33/44-198, the most promising vaccine candidate, was tested in three groups of ten mice each. One group received the purified protein alone; a second group received the protein plus an adjuvant called Alhydrogel; and a third group served as the control, receiving an injection of saline solution instead of the vaccine.

Purified RTA 1-33/44-198 protected 10 out of 10 mice from a whole-body aerosol challenge with lethal doses of ricin. The survival rate was the same with or without the adjuvant. All 10 animals in the unvaccinated control group died.

"Molecular modeling and protein engineering represent a significant step forward in vaccine development," said George V. Ludwig, Ph.D., acting science director for USAMRIID. "In the past, our reliance on using natural proteins and other immunogens limited our ability to make useable and producible vaccines. New techniques such as those described offer nearly unlimited possibilities."

According to Smith, the next step will be to test the new ricin vaccine in nonhuman primates. He said the team also is working to refine a scaled-up production method that is robust and reproducible. This involves optimizing the fermentation process, developing a process for purification, and refining the analytical methods for characterizing both the manufacturing process and the final product. In addition, USAMRIID is conducting pre-formulation studies to produce a formulated vaccine that will induce the optimum immune response possible in animal models.

Caree Vander Linden | EurekAlert!
Further information:
http://www.usamriid.army.mil

More articles from Life Sciences:

nachricht Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>